6 January 2026

DisCoVeRy publishes the 15-months results of the evaluation of AZD7442 (tixagevimab/cilgavimab) in hospitalized COVID-19 patients, including clinical, safety, seroneutralization, immunogenicity, and pharmacokinetics data

AZD7442 is a cocktail of two monoclonal antibodies (mAbs), tixagevimab and cilgavimab, derived from B cells obtained from patients who had recovered from SARS-CoV2 infection. In this phase 3, double-blind, randomized, multicenter trial, hospitalized adults with PCR-confirmed SARS-CoV-2 infection were randomized to receive AZD7442 or placebo, and followed-up until day 456, with repeated blood sample collections until day 365.

No significant differences were observed between treatment groups in clinical status, mortality, or SARS-CoV-2 reinfection. Safety profiles were similar between AZD7442 and placebo groups. Drug concentrations declined over time but remained detectable at day 365 for all sampled participants. Anti-drug antibodies positivity status did not seem to impact the concentration-time profiles of AZD7442. Neutralizing antibodies against the Delta variant were significantly higher in the AZD7442 group compared to placebo up to day 180, regardless of the vaccination or serology status (assessed up to day 90).

Link to the article published in CMI : https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(25)00623-8/abstract